By Claire Wingfield After 40 years of scientific stagnation, it is beginning to be an exciting time in tuberculosis treatment research. Tuberculosis (TB) is the leading killer of people with HIV worldwide, accounting for more than quarter of all HIV…
By Claire Wingfield After nearly 50 years, there is finally something to get excited about in tuberculosis (TB) drug development. Tibotec’s TMC207—the first compound from a novel class of TB drugs, the diarylquinolines—will likely be submitted to the U.S. Food…
by Javid Syed On December 8, 2010 the World Health Organization (WHO) endorsed the use of the new Xpert® MTB/RIF test as the initial test offered to people suspected of having HIV-associated TB or multidrug-resistant (MDR) TB. The test, developed…
HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development Second Edition September 2011 Written by Polly Clayden, Simon Collins, Mark Harrington, Richard Jefferys, Tracy Swan, Javid Syed, and Claire Wingfield with a a contribution…
July 2011 Globally in 2008 there were an estimated 440,00 cases of incident multidrug-resistant tuberculosis (MDR-TB). Despite international calls for action to reach universal access to TB treatment by 2015, governments and ministries of health in high-burden countries have not…
A strategic vision for R&D into point-of-care testing in resource-poor settings Tuberculosis (TB) remains a major challenge to public health globally, particularly in resource-poor settings. August 2011 – Although most cases of TB are curable, tuberculosis causes around 2 million…